Clinical Data Viridian reports positive results from elegrobart phase 3 trial PharmaTimesCompany says treatment shows strong efficacy and convenient dosing profileClinical DataRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) PharmaTimes Company says treatment shows strong efficacy and convenient dosing profile Clinical DataRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2DNext: FDA approves new high dose Spinraza regimen for SMA Related Stories Clinical Data Boehringer advances duo for aggressive cancers into phase 3 pharminent June 22, 2026 Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026 Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026
